Integrated genomics of ovarian xenograft tumor progression and chemotherapy response
<p>Abstract</p> <p>Background</p> <p>Ovarian cancer is the most deadly gynecological cancer with a very poor prognosis. Xenograft mouse models have proven to be one very useful tool in testing candidate therapeutic agents and gene function <it>in vivo</it>....
Main Authors: | Raphael Benjamin J, Singh Rakesh K, Ritz Anna, Kim Kyu K, Miller Daniel H, Hillenmeyer Sara, Fischer Andrew, Stuckey Ashley, Brard Laurent, Brodsky Alexander S |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2011-07-01
|
Series: | BMC Cancer |
Online Access: | http://www.biomedcentral.com/1471-2407/11/308 |
Similar Items
-
Identification of ovarian cancer metastatic miRNAs.
by: Souriya Vang, et al.
Published: (2013-01-01) -
Propranolol blocks osteosarcoma cell cycle progression, inhibits angiogenesis and slows xenograft growth in combination with cisplatin-based chemotherapy
by: Luisina M. Solernó, et al.
Published: (2022-09-01) -
A Novel Antibody-Drug Conjugate Targeting Nectin-2 Suppresses Ovarian Cancer Progression in Mouse Xenograft Models
by: Yun Hee Sim, et al.
Published: (2022-10-01) -
ABL001, a Bispecific Antibody Targeting VEGF and DLL4, with Chemotherapy, Synergistically Inhibits Tumor Progression in Xenograft Models
by: Dong-Hoon Yeom, et al.
Published: (2020-12-01) -
Factors that influence response classifications in chemotherapy treated patient-derived xenografts (PDX)
by: Joan E. Malcolm, et al.
Published: (2019-03-01)